Sandoz Biologics License Application for proposed
Submission supported by comprehensive analytical and clinical data package Denosumab indicated for treating variety of
Globe Newswire6-02-2023, 13:20
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability 3-09-2024, 19:00